First human trial launches for brain cancer vaccine

NCT ID NCT07422896

Not yet recruiting Disease control Sponsor: Catalina Lee Chang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new personalized vaccine called Bvax, made from each patient's own cells, combined with standard chemoradiation for newly diagnosed glioblastoma. The study will enroll 25 people to check safety and see if the vaccine helps control the cancer. It is the first time this approach is tested in humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B-cell vaccine (Bvax) plus autologous CD8 T cells
What this could lead to: If successful, this could point toward a new way to harness the immune system against glioblastoma, potentially improving survival when added to standard treatment.
What could go wrong: This is a very early, first-in-human trial with only 25 participants, so safety and effectiveness are not yet known. The vaccine is personalized and complex, which may limit scalability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Northwestern University

Chicago, Illinois, 60611, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.